Adult urologyRelief by botulinum toxin of voiding dysfunction due to benign prostatic hyperplasia: results of a randomized, placebo-controlled study
Section snippets
Material and methods
The study was conducted at Department of Surgery of the University Hospital Agostino Gemelli, Rome. The institutional review board approved the protocol for this double-blind, placebo-controlled study.
Results
Forty-two consecutive outpatients were assessed for eligibility. Of them, 8 patients did not meet the inclusion criteria and 4 patients refused to participate. Thus, 30 patients were randomized: 15 received BT and 15 placebo. No differences were found at baseline between the two groups (Table I). No complications during the procedure were observed in any patient.
Comment
BPH management is currently in transition.4, 5, 7 Although surgery will continue to be widely used, medical therapies are assuming increasing importance, owing to the desire of patients to avoid surgery whenever possible. A pilot study on the impact of a program to aid in decision-making about BPH showed a 40% decrease in the surgery rate in American patients.24 However, the goal of therapy is to relieve lower urinary tract symptoms. For this reason, the efficacy of any treatment for
Conclusions
We found BT injection into the prostate to be a promising approach to the treatment of BPH. It is well-tolerated and should be considered for patients who are at risk of surgery. Furthermore, it is not related to the patient’s willingness to complete treatment. Additional investigation of BT treatment is indicated before its general use can be advocated.
References (30)
- et al.
Guidelines for the diagnosis and treatment of benign prostatic hyperplasiaa comparative, international overview
Urology
(2001) - et al.
Transurethral resection of the prostate among Medicare beneficiaries in the United Statestime trends and outcomes
Urology
(1994) - et al.
Meta-analysis of randomized trials of terazosin in the treatment of benign prostatic hyperplasia
Urology
(2001) - et al.
Long-term, open-label, phase III multicenter study of tamsulosin in benign prostatic hyperplasia
Urology
(2001) - et al.
Anterior rectocele due to obstructed defecation relieved by botulinum toxin
Surgery
(2001) - et al.
Botulinum toxin urethral sphincter injection to restore bladder emptying in men and women with voiding dysfunction
J Urol
(2001) - et al.
Botulinum-A toxin for treating detrusor hyperreflexia in spinal cord injured patientsa new alternative to anticholinergic drugs? Preliminary results
J Urol
(2000) - et al.
Relief by botulinum toxin of voiding dysfunction due to prostatitis
Lancet
(1998) - et al.
Correlation of the American Urological Association symptom index with self-administered versions of the Madsen-Iversen, Boyarsky and Maine Medical Assessment Program symptom indexes
J Urol
(1992) - et al.
The American Urological Association symptom index for benign prostatic hyperplasia
J Urol
(1992)
Using repeated measures of symptom score, uroflowmetry and prostate specific antigen in the clinical management of prostate disease
J Urol
Comparison of the efficacy and safety of finasteride in older versus younger men with benign prostatic hyperplasia
Urology
Benign prostatic hyperplasia
J Urol
Histopathologic characterization of hereditary benign prostatic hyperplasia
Urology
Benign prostatic hyperplasiamedical and minimally invasive treatment options
N Engl J Med
Cited by (214)
Use of botulinum toxin A in pelvic floor dysfunctions in the elderly: A review
2019, Progres en UrologieSurgical Management of LUTS/BPH: New Mini-Invasive Techniques
2018, Lower Urinary Tract Symptoms and Benign Prostatic Hyperplasia: From Research to BedsideBotulinum toxin and benign prostatic hyperplasia
2018, Asian Journal of UrologyBotulinum toxin A treatment for lower urinary tract symptoms/benign prostatic hyperplasia
2017, Urological Science